KZR — Kezar Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Kezar Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -54.6 | -68.2 | -102 | -83.7 | -56 |
| Depreciation | |||||
| Non-Cash Items | 9.46 | 12.8 | 14.5 | 9.78 | 8.76 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.23 | -4.46 | 4.71 | -1.3 | -5.4 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -42.4 | -58.8 | -81.6 | -74.2 | -51.8 |
| Capital Expenditures | -0.316 | -1.58 | -1.81 | -0.029 | -0.008 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -28.1 | -89.8 | 77.9 | 80.5 | 92.5 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -28.4 | -91.4 | 76 | 80.4 | 92.5 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 113 | 128 | 0.638 | 0.103 | -10.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 41.7 | -22.4 | -4.96 | 6.26 | 30.1 |